Quintrio
Home

Stock overview

Trinity Biotech plc

TRIB

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.

Last trade $5.58
Day change +$0.205 (+3.81%)
Day range $5.53 – $6.26
Volume 19,279
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for TRIB.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for TRIB.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

Trinity Biotech announced continued execution of its transformation strategy, including commercial leadership strengthening in Europe, rollout of upgraded HbA1c column technology, and expansion of its PrePsia™ patent portfolio to nine patents. However, the company received a Nasdaq delisting notice after failing to maintain the $15 million minimum market value of publicly held shares requirement by the August 18, 2026 deadline. The company intends to request a hearing before a Nasdaq panel and is pursuing strategic initiatives to regain compliance.

GlobeNewswire Inc.

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Trinity Biotech plc received a non-compliance notice from Nasdaq on February 19, 2026, for failing to maintain the minimum market value of publicly held shares (MVPHS) of $15,000,000 required under Nasdaq Listing Rule 5450(b). The company has 180 calendar days until August 18, 2026, to regain compliance or face potential delisting. The ADSs will continue trading on Nasdaq Global Select Market under the symbol 'TRIB' during this period.

GlobeNewswire Inc.

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

Trinity Biotech plc received a non-compliance notice from Nasdaq on February 11, 2026, for failing to maintain the minimum bid price of $1.00 per share. The company has 180 calendar days until August 10, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. Management is evaluating options to cure the deficiency while the ADSs continue trading on the Nasdaq Global Select Market.

GlobeNewswire Inc.

Biosensors Market Size Expected to Reach USD 68.72 Billion by 2034

The global biosensors market is expected to grow from USD 30.04 billion in 2024 to USD 68.72 billion by 2034, with a CAGR of 8.64%. North America dominates the market, while Asia-Pacific shows the fastest growth potential, driven by chronic disease management and technological advancements.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jun 5, 2015$33.00Jul 1, 2015recurring
Jun 6, 2014$33.00Jul 1, 2014recurring
Jun 6, 2013$30.00Jul 1, 2013recurring
Jun 6, 2012$22.50Jun 22, 2012recurring
Jun 7, 2011$15.00Jun 23, 2011unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 24, 20261-for-30reverse split
Feb 23, 20241-for-5reverse split
Jun 2, 20051-for-4reverse split